The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDXHF | +2,525% | -76.91% | -25.41% | -84% |
| S&P | +14.43% | +77.25% | +12.13% | +278% |
MedX Health Corp. engages in the development, manufacture, and sale of medical device and software. It offers SIAscopy on DermSecure telemedicine platform, which is used to scan skin for suspicious moles and lesions, and phototherapeutic medical devices. Its brands include the DermSecure, MoleMate, SIMSYS, and SIAMETRICS. The company was founded on April 15, 1999 and is headquartered in Mississauga, Canada.
No news articles found for MedX Health.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $98.21K | 47.8% |
| Gross Profit | $21.33K | 9.8% |
| Gross Margin | 21.72% | -7.5% |
| Market Cap | $14.79M | 92.7% |
| Net Income | -$931.92K | -83.2% |
| EBITDA | -$628.60K | -80.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.34K | -84.0% |
| Accounts Receivable | $42.07K | 188.8% |
| Inventory | 0.3 | -4.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.08M | 55.4% |
| Short Term Debt | $4.96M | 5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -488.46% | -107.2% |
| Return On Invested Capital | 161.33% | -12.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$512.86K | 0.5% |
| Operating Free Cash Flow | -$512.86K | 0.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.03 | -0.03 | -0.03 | -2.30 | 83.36% |
| Price to Sales | 31.89 | 32.02 | 56.04 | 40.59 | -7.00% |
| Price to Tangible Book Value | -0.03 | -0.03 | -0.03 | -2.29 | 83.39% |
| Enterprise Value to EBITDA | -70.66 | -19.99 | -36.74 | -33.72 | -31.18% |
| Total Debt | $4.84M | $5.23M | $5.34M | $6.03M | 12.03% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
